Increased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis

Basit Öğe Kaydı
dc.authoridVural, Özge/0000-0001-7523-7553
dc.authorwosidCakir, Necati/AAG-7283-2019
dc.authorwosidTurgut, Burhan/A-2517-2016
dc.authorwosidVural, Özge/AAJ-6924-2021
dc.contributor.authorPamuk, Gulsum Emel
dc.contributor.authorTurgut, Burhan
dc.contributor.authorPamuk, Omer Nuri
dc.contributor.authorVural, Ozden
dc.contributor.authorDemir, Muzaffer
dc.contributor.authorCakir, Necati
dc.date.accessioned2024-06-12T11:12:27Z
dc.date.available2024-06-12T11:12:27Z
dc.date.issued2007
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPlatelet activation and circulating platelet-leucocyte complexes increase in vascular ischemic events and autoimmune inflammatory diseases. Platelet activation markers and platelet-leucocyte complexes were evaluated in primary Raynaud's phenomenon (RP) and in RP secondary to systemic sclerosis (SSc). Whole-blood flow cytometry was utilized to quantify CD62P, platelet microparticles (PMP), platelet-monocyte complexes (PMC) and platelet- neutrophil complexes (PNC) in primary RP and in SSc patients with secondary RP. SSc patients with secondary RP had significantly higher platelet CD62P expression than primary RP patients and controls (P= 0.017 and 0.004, respectively). Primary and secondary RP patients had higher mean PMC and PNC levels than controls (all P <= 0.001). PMP level in SSc patients with pulmonary hypertension was significantly higher than in others (P= 0.048). All parameters were similar in SSc patients with and without digital ulcers, aspirin-users and nonusers (P > 0.05). CD62P level decreased significantly after iloprost administration in four patients with digital ulcers (116.+/- 17.4 vs 7.4 +/- 3.8%, P= 0.03). Our results suggest there is platelet- leucocyte complex formation in RP, and, despite antithrombotic therapy, platelet activation and platelet-leucocyte interaction are ongoing in SSc. This is important as it might have potential therapeutic implications with respect to using antiplatelet drugs in SSc.en_US
dc.identifier.doi10.1097/MBC.0b013e328010bd05
dc.identifier.endpage302en_US
dc.identifier.issn0957-5235
dc.identifier.issn1473-5733
dc.identifier.issue4en_US
dc.identifier.pmid17473568en_US
dc.identifier.scopus2-s2.0-34247866412en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage297en_US
dc.identifier.urihttps://doi.org/10.1097/MBC.0b013e328010bd05
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23182
dc.identifier.volume18en_US
dc.identifier.wosWOS:000246795200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofBlood Coagulation & Fibrinolysisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPlatelet Activationen_US
dc.subjectPlatelet Microparticlesen_US
dc.subjectPlatelet-Monocyte Complexesen_US
dc.subjectPlatelet-Neutrophil Complexesen_US
dc.subjectPlatelet P-Selectinen_US
dc.subjectRaynaud's Phenomenonen_US
dc.subjectSystemic Sclerosisen_US
dc.subjectWhole-Blooden_US
dc.subjectRheumatoid-Arthritisen_US
dc.subjectActivationen_US
dc.subjectMicroparticlesen_US
dc.subjectBindingen_US
dc.subjectAggregationen_US
dc.subjectExpressionen_US
dc.subjectSelectinen_US
dc.subjectMarkersen_US
dc.titleIncreased circulating platelet-leucocyte complexes in patients with primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu